Drugs / POTASSIUM MAGNESIUM CITRATE (4:1:2)
last change Jul 2026 re-read 2 minutes ago

POTASSIUM MAGNESIUM CITRATE (4:1:2)

Small molecule

Developed for
hypertensive disorder · nephrolithiasis
Investigated by
University of Texas Southwestern Medical Center

Trials 5 · a red edge is where a trial was stopped

20102011201220132014201520162017201820192020202120222023202420252026202720282029203020312032
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT06819111 Jul 2026 → Jul 2027 expected nephrolithiasis University of Texas Southwestern Medical Center Not yet recruiting No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT01074918 Sep 2009 → Sep 2012 hypertensive disorder University of Texas Southwestern Medical Center Withdrawn No outcome recorded
Phase 22 trials
Phase 2 NCT05145309 Nov 2026 → Dec 2031 expected hypertensive disorder University of Texas Southwestern Medical Center Not yet recruiting No outcome recorded
Phase 2 NCT01682837 Oct 2012 → Mar 2015 hypertensive disorder University of Texas Southwestern Medical Center Completed No outcome recorded
Phase 41 trial
Phase 4 NCT02653560 Sep 2012 → Jan 2015 hypertensive disorder University of Texas Southwestern Medical Center Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
NCT02665117 Comparator Jan 2015 → Nov 2022 hypertensive disorder University of Texas Southwestern Medical Center Completed No outcome recorded

Evidence & citations 9 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as POTASSIUM MAGNESIUM CITRATE (4:1:2) ChEMBL registry synonym — accepted as the source's own label CHEMBL5314426
Known as Hcactive ChEMBL registry synonym — accepted as the source's own label CHEMBL5314426
Known as K-mag ChEMBL registry synonym — accepted as the source's own label CHEMBL5314426
Known as KMgCit “Drug: Potassium magnesium Citrate (KMgCit)” NCT02653560
1

NCT05145309

Known as Potassium magnesium citrate powder ClinicalTrials.gov intervention name — accepted as the source's own label NCT01682837
Known as Potassium-Magnesium Citrate “Patients will receive slow-release potassium citrate (UroCit-K), potassium magnesium citrate (powder), or potassium magnesium citrate (tablets).” NCT06819111
4

Potassium-Magnesium Citrate as a Blood Pressure Lowering Agent in Hypertensive Patients” NCT01074918

Potassium-Magnesium Citrate as a Blood Pressure Lowering Agent in Hypertensive Patients” NCT01074918

NCT02653560

NCT02665117

Known as Relyte ChEMBL registry synonym — accepted as the source's own label CHEMBL5314426
Modality Small molecule CHEMBL5314426
Route Oral “will be drunk with breakfast and again with dinner during the KMgCit Phase” NCT02653560